Clinical trial
An Open-Label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC47, a New Vaccine Against Streptococcus Pneumoniae, in Healthy Subjects.
NCT00873431 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC47, a New Vaccine Against Streptococcus Pneumoniae, in Healthy Subjects.
- Lead sponsor
- Valneva Austria GmbH
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 31, 2009
- Completion date
- February 28, 2010
- Enrollment
- 32 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.